Navigation Links
ATS Medical Participating in 44th Annual STS Annual Meeting
Date:1/24/2008

MINNEAPOLIS, Jan. 24 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI) is looking forward to its participation in the 44th Annual Meeting of the Society of Thoracic Surgeons (STS). The event runs January 28-30, 2008 in Fort Lauderdale, Florida, and serves as one of the year's key gatherings of cardiovascular surgeons from around the world.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

ATS Medical continues to broaden its exposure and relationships within the cardiac surgery community and the STS meeting provides an excellent opportunity to display the progress made in assembling an array of product offerings focused on meeting the evolving needs of cardiac surgeons. Featured products will include the company's flagship ATS Open Pivot(R) Heart Valve and our latest advancement, the ATS Open Pivot(R) AP360(TM). Recently approved in the US, the AP360 expands upon the fundamental strengths of the open pivot design by maximizing hemodynamic performance while incorporating a cuff design that will extend the valve's appeal to a broader spectrum of surgeon preferences.

ATS 3f(R) tissue heart valve products will be prominently featured. In-booth presentations on Monday, January 28th will include Dr. Richard Shemin, UCLA Medical Center, presenting a "Review of FDA Clinical Data with the ATS 3f(R) Aortic Bioprosthesis" and Professor Thierry Carrel, University Hospital of Berne, reporting on "Experience with the Sutureless ATS 3f Enable(TM) Aortic Bioprosthesis".

The ATS Simulus(R) annuloplasty product family, designed for the heart valve repair market segment, has expanded with the recent FDA approval of the ATS Simulus(R) Semi-Rigid Ring. This meeting will be the first market introduction of the semi rigid addition to the Simulus product line. The Simulus Semi Rigid ring includes the unique Flex-Zone(TM) anterior segment which respects the natural motion of the mitral annulus and its proximity to the aortic valve allowing for a safer, more physiologic valve repair.

Surgical treatment of cardiac arrhythmias continues to be a topic of great interest for surgeons and growing numbers find the ATS CryoMaze(TM) product line to be their therapy of choice. Dr. Harold Roberts, Florida Medical Center, will be presenting "CryoMaze Using Argon-Based Cryoablation is Highly Effective Therapy During Complex Valve Procedures" at the ATS booth on Tuesday, January 29th. In conjunction with East Carolina Heart Institute, ATS is sponsoring a scientific symposium focusing the treatment of atrial fibrillation, moderated by ATS Medical Director Dr. James L. Cox, and STS President Dr. W. Randolph Chitwood. Hands-on demonstrations of these market leading cryoablation technologies will be available at ATS Medical's booth #424.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair, and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2006 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
2. Medical University of South Carolina (MUSC) and Halsey Institute Create Partnership Between Art and Science
3. Aircraft Medical: European Patent Hearing
4. A Fort Worth Couple Sues Huguley Memorial Medical Center
5. Study raises questions about diagnosis, medical treatment of ADHD
6. MHA Insurance Company Offers Financial Incentive to Physician Policyholders Who Use Electronic Medical Records
7. Struggling Medical Delivery System Impacts Hospitals and Physicians Hardest
8. Aircraft Medical Ready to Fight
9. VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer
10. Hollywood Presbyterian Medical Center Responds to ACLU Lawsuit
11. Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Massachusetts (PRWEB) , ... March 30, 2017 , ... Youth ... had great success and feedback from high school and college students who have participated ... being held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear ... which retails normally at $29.97; for the remaining days of March, the price will ... reduced to a special price of just $10 (regular retail price $19.97). , The ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... , March 30, 2017 The topical ... $92.40 billion in 2016, growing at a CAGR of 6.4% ... is will be major end-user in market. While ... forecast period. ... Browse 87 tables and 41 figures, 10 Company profiles ...
(Date:3/30/2017)... -- Research and Markets has announced the addition ... Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, ... To 2025" report to their offering. ... The global hemodialysis ... billion by 2025. Home-based dialysis treatment ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: